Correction: Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for non-small cell lung cancer

Michela Terlizzi; Chiara Colarusso; Ilaria De Rosa; Nicolina De Rosa; Pasquale Somma; Carlo Curcio; Alessandro Sanduzzi; Pietro Micheli; Antonio Molino; Antonello Saccomanno; Rosario Salvi; Rita P. Aquino; Aldo Pinto; Rosalinda Sorrentino

doi:10.18632/oncotarget.25751

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for non-small cell lung cancer

PDF | How to cite

Oncotarget. 2018; 9:29537-29537. https://doi.org/10.18632/oncotarget.25751

Metrics: PDF 1518 views | ?

Michela Terlizzi¹, Chiara Colarusso^1,5, Ilaria De Rosa², Nicolina De Rosa², Pasquale Somma², Carlo Curcio³, Alessandro Sanduzzi⁴, Pietro Micheli², Antonio Molino⁴, Antonello Saccomanno¹, Rosario Salvi³, Rita P. Aquino¹, Aldo Pinto¹ and Rosalinda Sorrentino¹

¹ Department of Pharmacy, University of Salerno, ImmunePharma S.r.l., Fisciano, SA, Italy
² Anatomy and Pathology Unit, Ospedale dei Colli, AORN, “Monaldi”, Naples, Italy
³ Thoracic Surgery Unit, Ospedale dei Colli, AORN, “Monaldi”, Naples, Italy
⁴ Department of Respiratory Medicine, Respiratory Division, University of Naples Federico II, Fisciano, SA, Italy
⁵ PhD Program in Drug Discovery and Development, Department of Pharmacy, University of Salerno, Fisciano, SA, Italy

Published: June 29, 2018

This article has been corrected: The corrected author name is given below:

Alessandro Sanduzzi

Original article: 2018; 9:19356-19367. DOI: https://doi.org/10.18632/oncotarget.25049.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25751

Publication Alerts

Post-Publication Promotion

Corrections:

Correction: Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for non-small cell lung cancer